EGFR and neoplasm: Among these cases, we excluded those without data on RAS status, tumor sidedness, or target lesion measurements; those whose tumor evaluations were not performed at 8 ± 2 weeks; and where the participants were treated with an anti-EGFR antibody plus bevacizumab.